Cost effectiveness and cost utility analyses of finasteride therapy for the treatment of benign prostatic hyperplasia - systematic review
Baladi JF, Menon D
Record ID 31996008284
To examine the cost-effectiveness of finasteride therapy in the treatment of benign prostatic hyperplasia in Canadian provinces.
Authors' results and conclusions: Finasteride has a place in the management of benign prostatic hyperplasia. In patients with moderate symptoms, if offers increased health related quality of life compared to watchful waiting or TURP, but at a cost to the health care system.
Authors' recomendations: There is an economic/clinical argument for including finasteride in provincial drug plan formularies for a specific category of patient defined by its symptom severity and the time horizon involved in the drug therapy.
Project Status: Completed
URL for project: https://www.ccohta.ca/
Year Published: 1995
English language abstract: An English language summary is available
Publication Type: Not Assigned
- Decision Support Techniques
- Prostatic Hyperplasia
Organisation Name: Canadian Coordinating Office for Health Technology Assessment
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.